Previous 10 | Next 10 |
2024-06-09 16:23:25 ET Read the full article on Seeking Alpha For further details see: Stocks with the highest and lowest liquidity - Goldman Sachs
2024-06-09 12:43:21 ET More on Johnson & Johnson Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript) Johnson & Johnson: Vital Signs Decent, A Compelling V...
2024-06-07 14:23:26 ET More on NASDAQ Composite Index, S&P 500 Index, etc. The Fed Preview: Hawkish Turn Straight Into The Recession S&P 500 Earnings: Forward Estimates Continue To Be Revised Higher May Jobs Report: Surging Payrolls Likely Temper Rate Expecta...
2024-06-07 12:30:37 ET Summary iShares Global Healthcare ETF has underperformed the S&P 500 index in the past few years. IXJ has lower volatility and downside risk compared to the broader market. The healthcare sector is expected to have strong earnings growth in 2024 and ...
2024-06-07 12:04:12 ET More on Rapport Therapeutics, Inc. Rapport Therapeutics Seeks IPO For CNS Treatment Programs J&J-backed Rapport Therapeutics prices IPO at $17 per share J&J-backed Rapport Therapeutics sets terms for $136M IPO Financial informat...
2024-06-07 10:57:58 ET Summary Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter o...
2024-06-07 09:16:13 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...
2024-06-07 08:50:08 ET Summary "Dividend Aristocrats... in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 67 Aristocrats, screened as of June 5, 2024, represented all eleven Morningstar Secto...
2024-06-07 08:40:30 ET More on Johnson & Johnson Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript) Johnson & Johnson: Vital Signs Decent, A Compelling V...
2024-06-07 01:44:02 ET More on Rapport Therapeutics, Inc. Rapport Therapeutics Seeks IPO For CNS Treatment Programs J&J-backed Rapport Therapeutics sets terms for $136M IPO J&J-backed Rapport Therapeutics files for $100M IPO Financial information for ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:07 ET Narumi Nakagiri from Johnson Rice issued a price target of $150.00 for JNJ on 2024-07-23 04:56:00. The adjusted price target was set to $150.00. At the time of the announcement, JNJ was trading at $154.24. The overall price target consensus is at $...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with tr...
2024-07-18 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...